Riluzole-Loaded Nanostructured Lipid Carriers for Hyperproliferative Skin Diseases

Nanocarriers, and especially nanostructured lipid carriers (NLC), represent one of themost effective systems for topical drug administration. NLCs are biodegradable, biocompatible and provide a prolonged drug release. The glutamate release inhibitor Riluzole (RLZ) is a drug currently used for amyotro...

Descripción completa

Detalles Bibliográficos
Autores: Llorente, Xavier, Esteruelas Navarro, Gerard, Bonilla Vidal, Lorena, Garnica Agudelo, Mariana, Filgaira Enri, Ingrid, Lopez-Ramajo, Daniel, Gong, Ruoyi C., Soler Prat, Concepció, Espina García, Marta, García López, María Luisa, Manils Pacheco, Joan, Pujol Cubells, Montserrat, Sánchez-López, E. (Elena)
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/199761
Acceso en línea:https://hdl.handle.net/2445/199761
Access Level:acceso abierto
Palabra clave:Nanopartícules
Malalties de la pell
Nanoparticles
Skin diseases
Descripción
Sumario:Nanocarriers, and especially nanostructured lipid carriers (NLC), represent one of themost effective systems for topical drug administration. NLCs are biodegradable, biocompatible and provide a prolonged drug release. The glutamate release inhibitor Riluzole (RLZ) is a drug currently used for amyotrophic lateral sclerosis (ALS), with anti-proliferative effects potentially beneficial for diseases with excessive cell turnover. However, RLZ possesses low water solubility and high light- sensibility. We present here optimized NLCs loaded with RLZ (RLZ-NLCs) as a potential topical treatment. RLZ-NLCs were prepared by the hot-pressure homogenization method using active essential oils as liquid lipids, and optimized using the design of experiments approach. RLZ-NLCs were developed obtaining optimal properties for dermal application (mean size below 200 nm, negative surface charge and high RLZ entrapment efficacy). In vitro release study demonstrates that RLZ-NLCs allow the successful delivery of RLZ in a sustained manner. Moreover, RLZ-NLCs are not angiogenic and are able to inhibit keratinocyte cell proliferation. Hence, a NLCs delivery system loading RLZ in combination with natural essential oils constitutes a promising strategy against keratinocyte hyperproliferative conditions.

Similares en LA Referencia